CL2015003615A1 - Nucleósidos sustituidos, nucleótidos y análogos de los mismos. - Google Patents

Nucleósidos sustituidos, nucleótidos y análogos de los mismos.

Info

Publication number
CL2015003615A1
CL2015003615A1 CL2015003615A CL2015003615A CL2015003615A1 CL 2015003615 A1 CL2015003615 A1 CL 2015003615A1 CL 2015003615 A CL2015003615 A CL 2015003615A CL 2015003615 A CL2015003615 A CL 2015003615A CL 2015003615 A1 CL2015003615 A1 CL 2015003615A1
Authority
CL
Chile
Prior art keywords
nucleotides
analogs
substituted nucleosides
nucleosides
substituted
Prior art date
Application number
CL2015003615A
Other languages
English (en)
Spanish (es)
Inventor
Leonid Beigelman
Guangyl Wang
Natalia Dyatkina
Vivek Kumar Rajwanhi
Original Assignee
Alios Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc
Publication of CL2015003615A1 publication Critical patent/CL2015003615A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015003615A 2013-06-26 2015-12-14 Nucleósidos sustituidos, nucleótidos y análogos de los mismos. CL2015003615A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361839756P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
CL2015003615A1 true CL2015003615A1 (es) 2016-09-09

Family

ID=52116188

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003615A CL2015003615A1 (es) 2013-06-26 2015-12-14 Nucleósidos sustituidos, nucleótidos y análogos de los mismos.

Country Status (23)

Country Link
US (3) US9422322B2 (fr)
EP (2) EP3424938B1 (fr)
JP (2) JP6453322B2 (fr)
KR (1) KR20160023711A (fr)
CN (1) CN105408341B (fr)
AP (1) AP2015008954A0 (fr)
AU (2) AU2014302715B2 (fr)
BR (1) BR112015031763A2 (fr)
CA (1) CA2913210C (fr)
CL (1) CL2015003615A1 (fr)
DK (2) DK3424938T3 (fr)
EA (1) EA201592075A1 (fr)
ES (2) ES2825035T3 (fr)
GE (1) GEP201706793B (fr)
HK (1) HK1222178A1 (fr)
MX (1) MX2015017556A (fr)
NZ (1) NZ714415A (fr)
PE (1) PE20160205A1 (fr)
PH (1) PH12015502799A1 (fr)
SG (1) SG11201509585YA (fr)
TW (1) TWI655199B (fr)
UA (1) UA118760C2 (fr)
WO (1) WO2014209983A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2619215B1 (fr) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucléosides et analogues nucléotidiques
WO2012088155A1 (fr) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Analogues de nucléotides cycliques
EP2794630A4 (fr) 2011-12-22 2015-04-01 Alios Biopharma Inc Analogues de nucléotide phosphorothioate substitués
HUE041509T2 (hu) 2011-12-22 2019-05-28 Janssen Biopharma Inc Szubsztituált nukleozidok, nukleotidok és ezek analógjai
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
CA2894542C (fr) 2012-12-21 2023-10-31 Alios Biopharma, Inc. Nucleosides, nucleotides substitues et leurs analogues
CA2894541A1 (fr) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Nucleosides, nucleotides substitues et leurs analogues
AR099632A1 (es) 2013-04-05 2016-08-10 Alios Biopharma Inc Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
NZ714415A (en) 2013-06-26 2017-09-29 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP3013340B9 (fr) * 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Nucléosides, nucléotides substitués et leurs analogues
US9862743B2 (en) 2013-10-11 2018-01-09 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AP2016009653A0 (en) 2014-06-24 2016-12-31 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP3797782A1 (fr) 2014-06-24 2021-03-31 Janssen BioPharma, Inc. Nucléosides substitués, nucléotides et leurs analogues pour traiter les infections virales
WO2016022464A1 (fr) * 2014-08-05 2016-02-11 Alios Biopharma, Inc. Polythérapie pour traiter un paramyxovirus
EP3212657A4 (fr) 2014-10-28 2018-04-11 Alios Biopharma, Inc. Procédés de préparation d'analogues de nucléosides substitués
WO2016074596A1 (fr) * 2014-11-10 2016-05-19 南京曼杰生物科技有限公司 Dérivé de phosphoramidate de nucléoside et son application
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CA2979216A1 (fr) 2015-03-11 2016-09-15 Alios Biopharma, Inc. Composes d'aza-pyridone et leurs utilisations
CA2984421C (fr) * 2015-05-01 2024-04-09 Cocrystal Pharma, Inc. Analogues de nucleosides a utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer
LT3324977T (lt) 2015-07-22 2022-10-25 Enanta Pharmaceuticals, Inc. Benzodiazepino dariniai kaip rsv inhibitoriai
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
BR112020006334A2 (pt) * 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
CA3113425A1 (fr) * 2018-09-21 2020-03-26 Shanghai De Novo Pharmatech Co., Ltd. Analogue dinucleotidique cyclique, composition pharmaceutique associee et utilisation
UY38614A (es) 2019-03-18 2020-10-30 Enanta Pharm Inc Derivados de benzodiazepinas como inhibidores del rsv
WO2021216722A1 (fr) * 2020-04-23 2021-10-28 Atea Pharmaceuticals, Inc. Procédé stéréosélectif de fabrication de phosphoramidates de purine
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
CN114773417B (zh) * 2022-04-06 2023-08-22 郑州大学 一种虫草素磷酸酯及其制备方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
MY134070A (en) 2001-01-22 2007-11-30 Isis Pharmaceuticals Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2008334948B2 (en) 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
JP2012521359A (ja) 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
EP2619215B1 (fr) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucléosides et analogues nucléotidiques
GEP20156313B (en) 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012088155A1 (fr) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Analogues de nucléotides cycliques
HUE041509T2 (hu) 2011-12-22 2019-05-28 Janssen Biopharma Inc Szubsztituált nukleozidok, nukleotidok és ezek analógjai
EP2794630A4 (fr) 2011-12-22 2015-04-01 Alios Biopharma Inc Analogues de nucléotide phosphorothioate substitués
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
SG10201804571TA (en) 2012-03-21 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2013142159A1 (fr) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
EP2828278A4 (fr) 2012-03-21 2015-12-09 Alios Biopharma Inc Procédés de préparation d'analogues de nucléotide substitués
WO2013142157A1 (fr) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
CA2894541A1 (fr) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Nucleosides, nucleotides substitues et leurs analogues
CA2894542C (fr) 2012-12-21 2023-10-31 Alios Biopharma, Inc. Nucleosides, nucleotides substitues et leurs analogues
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2014164533A1 (fr) 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Méthodes de synthèse stéréosélective d'analogues nucléosidiques substitués
AR099632A1 (es) 2013-04-05 2016-08-10 Alios Biopharma Inc Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
EP3013340B9 (fr) 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Nucléosides, nucléotides substitués et leurs analogues
NZ714415A (en) * 2013-06-26 2017-09-29 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9862743B2 (en) 2013-10-11 2018-01-09 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EA201692473A1 (ru) 2014-06-24 2017-03-31 Элиос Биофарма, Инк. Способы получения замещенных нуклеотидных аналогов
EP3797782A1 (fr) 2014-06-24 2021-03-31 Janssen BioPharma, Inc. Nucléosides substitués, nucléotides et leurs analogues pour traiter les infections virales
AP2016009653A0 (en) 2014-06-24 2016-12-31 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US20160022724A1 (en) 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
WO2016022464A1 (fr) 2014-08-05 2016-02-11 Alios Biopharma, Inc. Polythérapie pour traiter un paramyxovirus
EP3212657A4 (fr) 2014-10-28 2018-04-11 Alios Biopharma, Inc. Procédés de préparation d'analogues de nucléosides substitués
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA45925A (fr) 2016-08-12 2019-06-19 Janssen Biopharma Inc Nucléosides et nucléotides substitués et leurs analogues
WO2018081449A1 (fr) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Méthode pour le traitement d'une infection par le virus respiratoire syncytial
EP3684782A1 (fr) 2017-09-18 2020-07-29 Janssen BioPharma, Inc. Nucléosides substitués, nucléotides et analogues de ceux-ci

Also Published As

Publication number Publication date
JP6453322B2 (ja) 2019-01-16
ES2825035T3 (es) 2021-05-14
US20160318967A1 (en) 2016-11-03
CN105408341A (zh) 2016-03-16
CA2913210C (fr) 2022-05-17
DK3424938T3 (da) 2020-10-12
GEP201706793B (en) 2017-12-11
EP3424938B1 (fr) 2020-07-22
ES2685591T3 (es) 2018-10-10
SG11201509585YA (en) 2015-12-30
CN105408341B (zh) 2019-06-21
EP3013843A4 (fr) 2016-11-23
JP2016523906A (ja) 2016-08-12
EP3013843B1 (fr) 2018-05-30
US20180194793A1 (en) 2018-07-12
CA2913210A1 (fr) 2014-12-31
US20150005251A1 (en) 2015-01-01
US10696708B2 (en) 2020-06-30
TWI655199B (zh) 2019-04-01
HK1222178A1 (zh) 2017-06-23
EP3424938A1 (fr) 2019-01-09
UA118760C2 (uk) 2019-03-11
AU2014302715B2 (en) 2018-12-06
JP2019059766A (ja) 2019-04-18
EA201592075A1 (ru) 2016-05-31
MX2015017556A (es) 2016-05-09
PE20160205A1 (es) 2016-05-21
US9932363B2 (en) 2018-04-03
DK3013843T3 (en) 2018-09-03
EP3013843A1 (fr) 2016-05-04
AU2014302715A1 (en) 2016-02-11
AP2015008954A0 (en) 2015-12-31
TW201542579A (zh) 2015-11-16
WO2014209983A1 (fr) 2014-12-31
AU2019201536A1 (en) 2019-03-28
US9422322B2 (en) 2016-08-23
NZ714415A (en) 2017-09-29
BR112015031763A2 (pt) 2017-08-29
KR20160023711A (ko) 2016-03-03
PH12015502799A1 (en) 2016-03-14

Similar Documents

Publication Publication Date Title
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2020000685A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de estos.
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
CL2016000381A1 (es) Compuestos antivirales
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2018001207A1 (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
CL2014001641A1 (es) Compuestos derivados de nucleosidos sustituidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y uso para mejorar o tratar una infeccion viral.
CL2015003370A1 (es) Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000539A1 (es) Compuestos aza-piridina y usos de los mismos
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2015001916A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral.
UY35266A (es) Compuestos antivirales
CL2014002392A1 (es) Uso de nucleosidos, nucleotidos sustituidos y análogos de los mismos para el tratamiento de una infeccion viral.
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
UY35300A (es) Formulación de combinación de dos compuestos antivirales
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
BR112016013714A2 (pt) compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêutica
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
DK3350163T3 (da) Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation